Ambrx Email Formats

Biotechnology Research • San Diego, California, United States • 51-100 Employees

Ambrx Email Formats

Ambrx uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 48.2% of the time.

Format	Example	Percentage
{first name}.{last name}@company.com	john.doe@company.com	48.2%
{first name initial}{last name}@company.com	{first name initial}doe@company.com	24.1%
{first name}@company.com	john@company.com	12.4%
{last name}.{first name}@company.com	doe.john@company.com	8.9%
{first name}{last name}@company.com	johndoe@company.com	6.4%

Key Contacts at Ambrx

Ricardo Burgos

Senior Director Quality

Mysore Ramprasad

Vice President, Pharmaceutical Development Ambrx & Director Biopharmaceutics Johnson & Johnson

Lisa Bé

Senior Director, Human Resources

Darryl Z. L'Heureux

Director, Clinical Science And Medical Affairs

Ying Buechler

Chief Technology Officer

Sunita Hack

Senior Director, Clinical And Program Strategy

Paige Odoh

Vice President, Pharmaceutical Development Ambrx & Director Biopharmaceuticals Johnson & Johnson

Mark Shimazu

Director - Upstream Process Development

Ying Sun

Associate Director Of Chemistry

Thuy Ccrp

Associate Director Of Clinical Operations

Company overview

Headquarters	10975 N Torrey Pines Rd, San Diego, CA 92037, US
Phone number	+18587293339
Website	ambrx.com
NAICS	541714
SIC	873
Founded	2003
Employees	51-100
Socials

About Ambrx

Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.